Peihong Wang
Guangzhou, 510180, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Corrigendum to "Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations" [Translational Oncology 58 (2025) 102467].
Journal: Translational oncology
Published: May 25, 2026
The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.
Journal: Molecular biomedicine
Published: January 28, 2026
Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.
Journal: European journal of pharmacology
Published: January 05, 2026
SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia.
Journal: NPJ precision oncology
Published: November 01, 2025
Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition.
Journal: Journal of translational medicine
Published: February 07, 2025
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy.
Journal: NPJ precision oncology
Published: January 17, 2025
Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations.
Journal: Translational oncology
Published: July 06, 2024
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
Journal: Cell communication and signaling : CCS
Published: April 17, 2024
Showing 1-8 of 8
Last Updated: 09/26/2026